175 related articles for article (PubMed ID: 35406609)
1. Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.
Kazerouni AS; Hormuth DA; Davis T; Bloom MJ; Mounho S; Rahman G; Virostko J; Yankeelov TE; Sorace AG
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406609
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Analysis of Longitudinal Quantitative MRI data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer.
Syed AK; Whisenant JG; Barnes SL; Sorace AG; Yankeelov TE
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32599906
[TBL] [Abstract][Full Text] [Related]
3. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2- Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy.
Weinfurtner RJ; Abdalah M; Stringfield O; Ataya D; Williams A; Mooney B; Rosa M; Lee MC; Khakpour N; Laronga C; Czerniecki B; Diaz R; Ahmed K; Washington I; Latifi K; Niell BL; Montejo M; Raghunand N
J Breast Imaging; 2022; 4(3):273-284. PubMed ID: 36686407
[TBL] [Abstract][Full Text] [Related]
5. Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma.
Slavkova KP; Patel SH; Cacini Z; Kazerouni AS; Gardner AL; Yankeelov TE; Hormuth DA
Sci Rep; 2023 Feb; 13(1):2916. PubMed ID: 36804605
[TBL] [Abstract][Full Text] [Related]
6. Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity.
Yuan Q; Kapur P; Zhang Y; Xi Y; Carvo I; Signoretti S; Dimitrov IE; Cadeddu JA; Margulis V; Brugarolas J; Madhuranthakam AJ; Pedrosa I
Clin Genitourin Cancer; 2016 Dec; 14(6):e585-e594. PubMed ID: 27209349
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
8. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
9. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-weighted imaging and dynamic contrast-enhanced MRI of experimental breast cancer bone metastases--a correlation study with histology.
Merz M; Seyler L; Bretschi M; Semmler W; Bäuerle T
Eur J Radiol; 2015 Apr; 84(4):623-30. PubMed ID: 25641009
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic efficacy of diffusion-weighted imaging and semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging in salivary gland tumors.
Gökçe E; Beyhan M
World J Radiol; 2023 Jan; 15(1):20-31. PubMed ID: 36721673
[TBL] [Abstract][Full Text] [Related]
12. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
13. Decoding the Heterogeneity of Malignant Gliomas by PET and MRI for Spatial Habitat Analysis of Hypoxia, Perfusion, and Diffusion Imaging: A Preliminary Study.
Bailo M; Pecco N; Callea M; Scifo P; Gagliardi F; Presotto L; Bettinardi V; Fallanca F; Mapelli P; Gianolli L; Doglioni C; Anzalone N; Picchio M; Mortini P; Falini A; Castellano A
Front Neurosci; 2022; 16():885291. PubMed ID: 35911979
[TBL] [Abstract][Full Text] [Related]
14. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma.
Park JE; Kim HS; Kim N; Kim YH; Kim JH; Kim E; Hwang J; Katscher U
Eur Radiol; 2021 Sep; 31(9):6655-6665. PubMed ID: 33880619
[TBL] [Abstract][Full Text] [Related]
15. Imaging Hallmarks of the Tumor Microenvironment in Glioblastoma Progression.
Walsh JJ; Parent M; Akif A; Adam LC; Maritim S; Mishra SK; Khan MH; Coman D; Hyder F
Front Oncol; 2021; 11():692650. PubMed ID: 34513675
[TBL] [Abstract][Full Text] [Related]
16. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
17. Tumor habitat analysis by magnetic resonance imaging distinguishes tumor progression from radiation necrosis in brain metastases after stereotactic radiosurgery.
Lee DH; Park JE; Kim N; Park SY; Kim YH; Cho YH; Kim HS
Eur Radiol; 2022 Jan; 32(1):497-507. PubMed ID: 34357451
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment.
Li SP; Padhani AR; Makris A
J Natl Cancer Inst Monogr; 2011; 2011(43):103-7. PubMed ID: 22043053
[TBL] [Abstract][Full Text] [Related]
19. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity.
Weinfurtner RJ; Raghunand N; Stringfield O; Abdalah M; Niell BL; Ataya D; Williams A; Mooney B; Rosa M; Lee MC; Khakpour N; Laronga C; Czerniecki B; Diaz R; Ahmed K; Washington I; Montejo M
Clin Breast Cancer; 2022 Feb; 22(2):e214-e223. PubMed ID: 34384695
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
